ADHD Drug Trial Showed Positive Results
Researchers tested ALKS 7290, a new drug targeting the brain's orexin system to treat ADHD symptoms.
Updated on Sept. 25, 2026 in Allergies
Live Poll
Would you trust a non-stimulant medication to manage ADHD symptoms more than traditional stimulant drugs?
Clinical trial results released last week indicate that the drug ALKS 7290 successfully improved attention and hyperactivity in adults. The study tested the medication against a placebo to determine its efficacy in managing ADHD.
Why it matters
Traditional ADHD stimulants can pose risks including hypertension and potential addiction. ALKS 7290 offers a potential alternative by stimulating the brain's orexin system rather than dopamine and noradrenaline levels.
In a clinical trial of 50 adults, those on the highest dose of ALKS 7290 shifted from severe to mild ADHD ratings. The two-week study observed no concerning changes in heart rate or blood pressure.
The players
Virginia Tech
Virginia Tech is the research institution responsible for conducting the study on ALKS 7290.
The details
The drug functions by stimulating the orexin system to control wakefulness and attention. While participants reported common side effects like dizziness, insomnia, constipation, and frequent urination, the initial findings suggest a therapeutic benefit for ADHD.
Timeline
Last week: The early clinical trial results were released.
Two weeks: The duration of the clinical trial for ALKS 7290.
Within five years: The potential timeline for the commercial availability of the medication.
The Big Picture
This study follows the research pattern established in the field of orexin-based neuropharmacology by applying the mechanism to cognitive regulation. The findings bridge gaps between sleep-wake research and the management of neurodevelopmental conditions.
If approved, this medication could provide an alternative for patients who cannot tolerate the side effects of traditional stimulants. Patients should monitor future trial updates to see how this drug compares to current standard treatments.
The takeaway
While early data is promising, the transition from severe to mild symptom ratings requires validation in larger, long-term studies. Patients should continue consulting with their healthcare providers regarding the risks and benefits of existing stimulant medications.
What happens next
A larger clinical trial involving more than 300 patients is currently underway to further evaluate the drug's efficacy and safety.
Further reading
For more on the current landscape of treating attention-related conditions, visit our Allergies section.
Live Poll
Would you trust a non-stimulant medication to manage ADHD symptoms more than traditional stimulant drugs?
